Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 63, Issue 1, 2009, Pages 119-121

  Srivastava, Ashish ^a,b   Borkar, Hirabai A ^a   Chandak, Sumitkumar ^a  

^a Institute of Psychiatry and Human Behaviour   (India)

^b Residents Hostel   (India)

Author keywords

Neuroleptic malignant syndrome; Olanzapine; Schizophrenia

Indexed keywords

ALPRAZOLAM; AMISULPRIDE; AMOXICILLIN; BROMOCRIPTINE; CHLORDIAZEPOXIDE; CLONAZEPAM; ESCITALOPRAM; FLUOXETINE; LORAZEPAM; OLANZAPINE; THIORIDAZINE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL;

ADULT; ANAMNESIS; ARTICLE; BRADYKINESIA; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG EFFICACY; HUMAN; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PARANOID SCHIZOPHRENIA; SALIVATION; SIDE EFFECT; SLEEP DISORDER; TREATMENT DURATION; TREMOR;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CONSCIOUSNESS; HUMANS; HYPNOTICS AND SEDATIVES; LORAZEPAM; MALE; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; SCHIZOPHRENIA, PARANOID; TOMOGRAPHY, X-RAY COMPUTED;

EID: 58449118573     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2008.01894.x     Document Type: Article

References (16)

1. Tsai G, Cristomo G, Rosenblat MS. Neuroleptic malignant syndrome associated with clozapine. Ann. Clin. Psychiatry 1995 7 : 91 95.
2. Meterissian GB. Risperidone-induced neuroleptic malignant syndrome: A case report and review. Can. J. Psychiatry 1996 41 : 52 54.
3. Filice GA, McDougall BC, Ercan-Fang N et al. Neuroleptic malignant syndrome associated with olanzapine. Ann. Pharmacother. 1998 32 : 1158 1160.
4. Waring WS, Wrate J, Bateman DN. Olanzapine overdose is associated with acute muscle toxicity. Hum. Exp. Toxicol. 2006 25 : 735 740.
5. Fernandez MZ, Garcia TE. Olanzapine-induced neuroleptic malignant syndrome. Actas Esp. Psiquiatr. 2006 34 : 144 145.
6. Kogoj A, Velikonja I. Olanzapine-induced neuroleptic malignant syndrome: A case review. Hum. Psychopharmacol. Clin. Exp. 2003 18 : 301 309.
7. Caroff SN, Mann SC. Neuroleptic malignant syndrome: A review. Med. Clin. North Am. 1993 77 : 185 202.
8. Ebadi M, Pfeiffer RF, Murrin LC. Pathogenesis and treatment of neuroleptic malignant syndrome: A review. Gen. Pharmacol. 1990 21 : 367 386.
9. Heiman-Patterson PD. Neuroleptic malignant syndrome and malignant hyperthermia: Important issues for medical consultant (review). Med. Clin. North Am. 1993 77 : 477 492.
10. Gurrea RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am. J. Psychiatry 1999 157 : 310 311.
11. Margetic B, Aukst-Margetic B. Neuroleptic malignant syndrome and clozapine withdrawal at the same time? Prog. Neuropsychopharmacol. Biol. Psychiatry 2005 29 : 145 147.
12. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: A review and critique. Am. J. Psychiatry 1998 155 : 1113 1116.
13. Velamoor VR, Norman RMG, Caroff SN, Mann SC, Sullivan KA. Progression of symptoms in neuroleptic malignant syndrome. J. Nerv. Ment. Dis. 1994 182 : 168 173.
14. Adityanjee CHM. Neuroleptic malignant syndrome after neuroleptic discontinuation. Prog. Neuropsychopharmacol. Biol. Psychiatry 1989 19 : 1323 1334.
15. John M, Davy's MD, Philip G et al. Neuroleptic malignant syndrome. In : Dunner DL (ed). Current psychiatric therapy. Harcourt Broce Jovanich Ync, Philadelphia, PA, 1993 170 175.
16. Crespo FB, Carbonell MC. Sindrome neuroleptico maligno: Una revision bibiliographica. Actas Luso Esp Neurol. Psiquiatr. Cienc. Afines 1995 23 : 273 278.